ColgatePalmolive (CL)
(Delayed Data from NYSE)
$97.95 USD
-0.13 (-0.13%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $98.50 +0.55 (0.56%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth B Momentum B VGM
Price, Consensus and EPS Surprise
CL 97.95 -0.13(-0.13%)
Will CL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CL
Pilgrim's Pride (PPC) Up 42.3% YTD: What's Ahead for the Stock?
Will Strong Volume & Pricing Aid Colgate's (CL) Q2 Earnings?
CL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Lamb Weston (LW) Top Estimates in Q4 Earnings Release?
Newell (NWL) Gears Up for Q2 Earnings: What You Should Know
Columbia Sportswear (COLM) Q2 Earnings Coming Up: Things to Note
Other News for CL
Cannabis Is Flying Off The Shelves In These Five States, Earning Billions For Marijuana Companies
Colgate-Palmolive price target raised by $14 at JPMorgan, here's why
J.P. Morgan Reaffirms Their Buy Rating on Colgate-Palmolive (CL)
Colgate-Palmolive price target raised by $10 at Stifel, here's why
Colgate-Palmolive: A Strong Buy on Innovation, Market Dominance, and Growth Potential